ArticlePloS one2025
In vitro and in vivo approaches demonstrating the antiproliferative activity of pomegranate seed proteins and peptides on breast cancer.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pomegranate seed proteins and peptides exhibit high antioxidant capacity according to previous work carried out by our group. The present work aims to evaluate the antitumoral potential of pomegranate seed protein isolates (PIs), obtained using two different procedures, pressurized liquids (PLE) and high-intensity focused ultrasounds (HIFU), and their hydrolysates on breast cancer cells (HCC1806) and immunodeficient mice (Hsd:Athymic Nude-Foxn1nu). The treatment of HCC1806 cells with increasing concentrations of pomegranate seed PIs and the hydrolysates significantly reduced cell viability. At a concentration of 4 mg/mL (PLE PI), 2 mg/mL (HIFU PI), and 2.4 mg/mL (hydrolysates), all treatments significantly reduced breast cancer cell migration and metalloproteinase 9 (MMP-9) activity (active and pro form), and enhanced cell adhesion. Additionally, a reduction in the proliferation capacity of HCC1806 cells was observed, most likely due to cell cycle arrest and the apoptotic effect of PLE PI and its hydrolysate. In vivo experiments with pomegranate seed hydrolysates confirmed their antitumoral capacity, observing significant reductions in the tumor volume and weight after treating with pomegranate proteins and peptides, as well as in metalloproteinase (MMP) activity and vascular endothelial growth factor (VEGF) expression. In addition to proteins and peptides, the anticancer potential may also be related to the presence of phenolic compounds, especially abundant in the PLE extracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.